Search
Menu
Home
HTB
2003
February
HTB
February 2003
Contents
Editorial
Volume 4 Number 1 January/February 2003
Conference reports
6th International Congress on Drug Therapy in HIV Infection, 17-21 November 2002, Glasgow, UK
Combination of three generic drugs in one pill meets bioequivalence criteria when compared with the branded drugs: Triomune vs d4T/3TC/NVP
An overview of the conference
Pharmacokinetic evaluation of tenofovir and enteric-coated ddI
The advantages of fosamprenavir; comparing saquinavir/r to lopinavir/r; reducing viral load to <3 copies; AZT-d4T cross resistance; and rising HCV rates
Promising data regarding DermaVir for therapeutic vaccine
Enfuvirtide (T-20): predicting success and modelling survival benefits
Virologic failure among treatment-naive patients taking tenofovir DF or stavudine in combination with lamivudine and efavirenz
Comparison of the efficacy and safety of tenofovir vs. d4T when used in combination with 3TC and efavirenz in ARV-naive patients
Safety profile of tenofovir in treatment-experienced patients
Antiretrovirals
Roche and Trimeris able to make enough enfuvirtide (T-20) for only 12,000 people this year, 32,000 next year, citing difficulties in the manufacturing process
Vertex Pharmaceuticals announces submission of NDA/MAA filings in US and Europe for amprenavir pro-drug (GW433908)
BMS submits new drug application for investigational protease inhibitior atazanavir
Europe and America approve once-a-day stavudine (d4T, Zerit)
Tenofovir as HIV prevention: study to reduce HIV transmission in sexually active adults
Boehringer chooses dose for phase III studies of tipranavir/ritonavir PI combination
Treatment access
Lancet special report examines direction new WHO director general should take on several HIV/AIDS-related issues
Lipodystrophy and metabolic complications
Adipose tissue alterations develop early in antiretroviral therapy
Basic science and immunology
Breadth of memory CTL response against HIV associated with immune control
Dendritic-cell vaccine elicits strong anti-SIV response in monkeys
HIV infection causes fibrosis in lymphatic tissue, diminishing CD4+ pool
Chronic immune activation: a lethal factor in HIV infection?
Other news
Website run by a nun in a caravan is nominated for awards
Infection by closely related HIV strains possible
On the web
Report from the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV
The science of side effects (or, who’s afraid of 3T3-F44A2 cells?)
Medscape conference coverage, based on selected sessions at the 6th International Congress on Drug Therapy in HIV Infection
4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV
T-20: a model for novel anti-HIV drugs in development
Recent research in HIV infection: Part 1
Medscape coverage: HIV/AIDS-related research at the 40th Annual Meeting of the Infectious Diseases Society of America
HIV-associated sensory neuropathies
New HIV Insite Knowledge Base chapters
Protease inhibitor double boosting
Historical essays from Science
Treatment of primary HIV infection
Lipodystrophy: lack of agreement on definition and etiology presents a challenge to research and therapy
Navigating resistance pathways
PDFs
Volume 4 Number 1 January/February 2003 PDF
HTB RSS
Early access
Unheard: The medical practice of silencing – by Dr Rageshri Dhairyawan
9 November 2024
Bipolar disorder in people living with HIV
1 November 2024
Mpox breakthrough cases after two doses of the MVA-BN vaccine
1 November 2024
Management of drug resistance to integrase inhibitors: results from an international perinatal virtual clinic
1 November 2024
All early access reports
Current issues
November 2024
October 2024
September 2024
Back issues
Special report
HTB news: i-Base changes during 2024
1 November 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate